THERAPY DOSSIER · th-d6710c37d0ca

BQ-869

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25973006 ↗2015Reported benefit

BQ-869, a novel NMDA receptor antagonist, protects against excitotoxicity and attenuates cerebral ischemic injury in stroke.

RatIschaemia-reperfusionCerebral (MCAO/stroke)Sprague-Dawley

Model: Middle cerebral artery occlusion (reported as MACO) focal cerebral ischaemia in rats, with companion in vitro NMDA excitotoxicity work in hippocampal pyramidal neurons

BQ-869 blocked NMDA receptors in a concentration- and dose-dependent manner, reduced NMDA-induced calcium influx, improved motor ability, decreased infarct size and reduced mortality in rats with focal cerebral ischaemia.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…